Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
Linda Petrone, Carla Tortorella, Alessandra Aiello, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 24

Showing 24 citing articles:

Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis
Alba Grifoni, Tonino Alonzi, Galit Alter, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 49
The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic
Linda Petrone, Alessandro Sette, Rory D. de Vries, et al.
Pathogens (2023) Vol. 12, Iss. 7, pp. 862-862
Open Access | Times Cited: 25
Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases
Linda Petrone, Andrea Picchianti Diamanti, Gian Domenico Sebastiani, et al.
International Journal of Infectious Diseases (2022) Vol. 121, pp. 24-30
Open Access | Times Cited: 29
Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
Alessandra Aiello, Andrea Coppola, Valentina Vanini, et al.
International Journal of Infectious Diseases (2022) Vol. 122, pp. 841-849
Open Access | Times Cited: 29
Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
Alessandra Aiello, Saeid Najafi Fard, Delia Goletti
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
The MegaPool Approach to Characterize Adaptive CD4+ and CD8+ T Cell Responses
Ricardo da Silva Antunes, Daniela Weiskopf, John Sidney, et al.
Current Protocols (2023) Vol. 3, Iss. 11
Open Access | Times Cited: 15
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
Alessandra Aiello, Andrea Coppola, Serena Ruggieri, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 94, Iss. 4, pp. 290-299
Open Access | Times Cited: 22
Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report
Serena Vita, Alessandra D’Abramo, Andrea Coppola, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
Serena Ruggieri, Alessandra Aiello, Carla Tortorella, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8525-8525
Open Access | Times Cited: 10
Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases
Tonino Alonzi, Alessandra Aiello, Michela Sali, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117153-117153
Open Access | Times Cited: 3
Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
Alessandra Aiello, Adriano Grossi, Silvia Meschi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
COVID-19 and multiple sclerosis: challenges and lessons for patient care
Luca Prosperini, Georgina Arrambide, Elisabeth Gulowsen Celius, et al.
The Lancet Regional Health - Europe (2024) Vol. 44, pp. 100979-100979
Open Access | Times Cited: 2
Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy
Saeid Najafi Fard, Elisa Petruccioli, Chiara Farroni, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis
Gianfranco Alicandro, B.S. Orena, Chiara Rosazza, et al.
Vaccine (2023) Vol. 41, Iss. 28, pp. 4114-4120
Open Access | Times Cited: 4
Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma
Léa Da Silva, Timothée Klopfenstein, Vincent Gendrin, et al.
Viruses (2023) Vol. 15, Iss. 11, pp. 2220-2220
Open Access | Times Cited: 3
Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity
Katie E. Lineburg, Pauline Crooks, Jyothy Raju, et al.
iScience (2023) Vol. 26, Iss. 12, pp. 108474-108474
Open Access | Times Cited: 3
Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination
Yapei Huang, Juliana Shin, Alexander M. Xu, et al.
iScience (2022) Vol. 25, Iss. 10, pp. 105209-105209
Open Access | Times Cited: 4
Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination
Ilya Kister, Ryan Curtin, Amanda L. Piquet, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination
Ilya Kister, Ryan Curtin, Amanda L. Piquet, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 7, pp. 1750-1764
Open Access
Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination
Alessandra Aiello, Serena Ruggieri, Assunta Navarra, et al.
Vaccines (2024) Vol. 12, Iss. 8, pp. 926-926
Open Access
Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later
Rocío Rubio, Alexei Yavlinsky, Marina Escalera Zamudio, et al.
Journal of Infection (2024), pp. 106402-106402
Open Access
Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis
Markus Breu, Christian Lechner, Lisa Schneider, et al.
Pediatric Neurology (2023) Vol. 143, pp. 19-25
Open Access | Times Cited: 1
The Covid-19 and TB Syndemic: Differences and Similarities
Stefan H. E. Kaufmann, Alan Sher, Alex Sigal, et al.
Frontiers research topics (2023)
Open Access
Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis
Markus Breu, Christian Lechner, Lisa Schneider, et al.
SSRN Electronic Journal (2022)
Closed Access
Page 1

Scroll to top